Goldman Sachs: Top Q3 Healthcare Stocks We Own

Wall St. Watchdog reveals information regarding Goldman Sachs Group’s top holdings in the Healthcare sector for the quarter ending September 30th, 2011. The firm held 558 stocks in the Healthcare sector at the end of the quarter with an aggregate market value of $8.741 billion.

  • Merck & Co. Inc. (NYSE:MRK): On 06/30/2011 reported holding 24,909,116 shares with a market value of $879,042,726. This comprised 0.58% of the total portfolio. On 09/30/2011 reported holding 23,979,546 shares with a market value of $784,131,172. This comprised 0.61% of the total portfolio. The net change in shares for this position over the two quarters is -929,570. About Company: Merck & Co., Inc. is a global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of human and animal health products. Merck’s products include a treatment for elevated cholesterol, a treatment for male pattern hair loss, a preventive treatment for osteoporosis, a treatment for hypertension, and a treatment for allergic rhinitis.
  • Johnson & Johnson (NYSE:JNJ): On 06/30/2011 reported holding 11,377,408 shares with a market value of $756,825,142. This comprised 0.5% of the total portfolio. On 09/30/2011 reported holding 8,817,087 shares with a market value of $561,560,259. This comprised 0.44% of the total portfolio. The net change in shares for this position over the two quarters is -2,560,321. About Company: Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
  • Thermo Fisher Scientific Inc. (NYSE:TMO): On 06/30/2011 reported holding 11,029,900 shares with a market value of $710,215,254. This comprised 0.47% of the total portfolio. On 09/30/2011 reported holding 10,240,938 shares with a market value of $518,601,094. This comprised 0.4% of the total portfolio. The net change in shares for this position over the two quarters is -788,962. About Company: Thermo Fisher Scientific, Inc. manufactures scientific instruments, consumables, and chemicals. The Company offers analytical instruments, laboratory equipment, software, services, consumables, reagents, chemicals, and supplies to pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions, and government agencies.
  • St. Jude Medical Inc. (NYSE:STJ): On 06/30/2011 reported holding 13,234,646 shares with a market value of $631,027,925. This comprised 0.42% of the total portfolio. On 09/30/2011 reported holding 13,161,666 shares with a market value of $476,320,674. This comprised 0.37% of the total portfolio. The net change in shares for this position over the two quarters is -72,980. About Company: St. Jude Medical, Inc. develops, manufactures, and distributes medical devices for the worldwide cardiovascular market. The Company serves patients and its health care customers with products and services including heart valves, cardiac rhythm management systems, specialty catheters, and other cardiovascular devices.
  • Teva Pharmaceutical Industries Limited (NASDAQ:TEVA): On 06/30/2011 reported holding 12,098,928 shares with a market value of $583,410,323. This comprised 0.38% of the total portfolio. On 09/30/2011 reported holding 11,948,972 shares with a market value of $444,740,752. This comprised 0.35% of the total portfolio. The net change in shares for this position over the two quarters is -149,956. About Company: Teva Pharmaceutical Industries Ltd. develops, manufactures and markets generic and branded human pharmaceuticals and active pharmaceutical ingredients. The Company produces antibiotics, oncological products, Alpha D3 for treatment of post-menopausal bone loss in women and Copaxone for treatment of multiple sclerosis. Teva develops novel drugs for diseases of the central nervous system.
  • Pfizer Inc. (NYSE:PFE): On 06/30/2011 reported holding 27,379,087 shares with a market value of $564,009,203. This comprised 0.37% of the total portfolio. On 09/30/2011 reported holding 24,836,260 shares with a market value of $439,105,084. This comprised 0.34% of the total portfolio. The net change in shares for this position over the two quarters is -2,542,827. About Company: Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company’s products include prescription pharmaceuticals, non-prescription self-medications, and animal health products such as anti-infective medicines and vaccines.
  • Boston Scientific Corporation (NYSE:BSX): On 06/30/2011 reported holding 64,221,843 shares with a market value of $443,772,925. This comprised 0.29% of the total portfolio. On 09/30/2011 reported holding 66,383,375 shares with a market value of $392,325,736. This comprised 0.31% of the total portfolio. The net change in shares for this position over the two quarters is 2,161,532. About Company: Boston Scientific Corporation develops, manufactures, and markets minimally invasive medical devices. The Company’s products are used in interventional cardiology, cardiac rhythm management, peripheral interventions, electrophysiology, neurovascular intervention, endoscopy, urology, gynecology and neuromodulation.
  • Wellpoint Inc. (NYSE:WLP): On 06/30/2011 reported holding 6,649,420 shares with a market value of $523,774,791. This comprised 0.34% of the total portfolio. On 09/30/2011 reported holding 5,894,492 shares with a market value of $384,792,431. This comprised 0.3% of the total portfolio. The net change in shares for this position over the two quarters is -754,928. About Company: WellPoint Inc. is a health benefits company. The Company provides health benefits, dental and vision benefits, pharmacy benefits, life insurance, and life and disability insurance benefits. WellPoint operations include Blue Cross and Blue Shield plans.
  • Eli Lilly & Co. (NYSE:LLY): On 06/30/2011 reported holding 8,307,867 shares with a market value of $311,794,238. This comprised 0.21% of the total portfolio. On 09/30/2011 reported holding 8,514,345 shares with a market value of $314,775,345. This comprised 0.25% of the total portfolio. The net change in shares for this position over the two quarters is 206,478. About Company: Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company’s products are sold in countries around the world. Eli Lilly’s products include neuroscience products, endocrine products, anti-infectives, cardiovascular agents, oncology products, and animal health products.
  • Gilead Sciences Inc. (NASDAQ:GILD): On 06/30/2011 reported holding 8,147,797 shares with a market value of $337,400,273. This comprised 0.22% of the total portfolio. On 09/30/2011 reported holding 7,376,061 shares with a market value of $286,191,161. This comprised 0.22% of the total portfolio. The net change in shares for this position over the two quarters is -771,736. About Company: Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. The Company’s primary arees of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions.

(Note: Data regarding Goldman Sachs Group’s stock holdings are sourced from whalewisdom.com. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>

More from The Cheat Sheet